As shown in Figure S4, NCKAP1 showed negative correlations with all these immune signatures and exhibited a poor prognosis across multiple cancers, including BRCA, cervical squamous cell carcinoma (CESC), head and neck squamous cell carcinoma (HNSC), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pancreatic adenocarcinoma (PAAD), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), and uterine carcinosarcoma (UCS). Here, NCKAP1 is linked to cancer.